Arix Bioscience PLC has announced the results of its First General Meeting, where the Resolution proposed to approve the recommended all-share acquisition of Arix's assets by RTW Bio was passed by the requisite majority of Shareholders. The Resolution also authorized the Board and the Liquidators to implement the Scheme, empowered the Liquidators to accept the Consideration Shares for distribution to eligible Shareholders, and applied to delist the Shares. The full text of the Resolution is available on Arix's website.
The voting results showed that 92.22% of the votes were cast in favor of the Resolution, with 7.78% against it. The next step in the process is the Second General Meeting, which will be held on 12 February 2024. Shareholders are requested to complete, sign, and return the form of proxy for the Second General Meeting by 8 February 2024. The Resolution to be considered at the Second General Meeting will require the approval of at least 75% of the votes cast in respect of it.
The completion of the Scheme remains subject to the passing of the Resolution at the Second General Meeting. The Resolution, if passed, will place the Company into members' voluntary liquidation, appoint the Liquidators, and authorize the Liquidators to exercise certain powers for which the express sanction of Shareholders is required.
Enquiries regarding this matter can be directed to Arix Bioscience plc, Jefferies (Financial Adviser & Corporate Broker to Arix), and Powerscourt Group (PR & Communications adviser to Arix).
This announcement contains important information regarding the acquisition and the parties involved in the process. Jefferies International Limited is acting exclusively for Arix in connection with the matters set out in this announcement.